Abstract
Prion diseases, including Creutzfeldt–Jakob disease, are mediated by transmissible proteinaceous pathogens. Pathological changes indicative of neuro-degeneration have been observed in the brains of affected patients. Simultaneously, microglial activation, along with the upregulation of pro-inflammatory cytokines, including IL-1 or TNF-α, have also been observed in brain tissue of these patients. Consequently, pro-inflammatory cytokines are thought to be involved in the pathogenesis of these diseases. Accelerated prion infections have been seen in interleukin-10 knockout mice, and type 1 interferons have been found to be protective against these diseases. Since interleukin-10 and type 1 interferons are key mediators of the antiviral THαβ immunological pathway, protective host immunity against prion diseases may be regulated via THαβ immunity. Currently no effective treatment strategies exist for prion disease; however, drugs that target the regulation of IL-10, IFN-alpha, or IFN-β, and consequently modulate the THαβ immunological pathway, may prove to be effective therapeutic options.
Subject
Virology,Infectious Diseases
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Type 2 hypersensitivity disorders, including systemic lupus erythematosus, Sjögren’s syndrome, Graves’ disease, myasthenia gravis, immune thrombocytopenia, autoimmune haemolytic anaemia, dermatomyositis, and graft-versus-host disease, are THαβ-dominant autoimmune diseases;Virulence;2024-09-12
2. Types of cell death and their relations to host immunological pathways;Aging;2024-08-08
3. Role of TGFβ-producing regulatory T cells in scleroderma and end-stage organ failure;Heliyon;2024-08
4. Interplay of Chemokines Receptors, Toll-like Receptors, and Host Immunological Pathways;Biomedicines;2023-08-25
5. An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications;Virulence;2023-03-16